Lexeo Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| EBT Margin | -3,211.86% | |||||||||||||||
| EBIT Margin | -3,292.28% | |||||||||||||||
| EBITDA Margin | -3,292.28% | |||||||||||||||
| Operating Margin | -3,292.28% | |||||||||||||||
| Net Margin | -3,211.86% | |||||||||||||||
| Efficiency | ||||||||||||||||
| Assets AverageAssets Avg. | 97.27M | 176.51M | 202.61M | 182.94M | 160.40M | 136.32M | 150.88M | 159.96M | 206.27M | 259.52M | 252.63M | |||||
| Invested CapitalInvested Cap. | -158.66M | |||||||||||||||
| Leverage & Solvency | ||||||||||||||||
| Interest Coverage RatioInterest Cover | -602.83 | -281.43 | -385.80 | -263.68 | -389.87 | -299.48 | -629.49 | -672.86 | -901.23 | -912.73 | -0.00M | -0.00M | -984.00 | -0.00M | -0.00M | -0.00M |
| Debt Ratio | 0.08 | |||||||||||||||
| Times Interest Earned | -602.83 | -281.43 | -385.80 | -263.68 | -389.87 | -299.48 | -629.49 | -672.86 | -901.23 | -912.73 | -0.00M | -0.00M | -984.00 | -0.00M | -0.00M | -0.00M |
| Valuation | ||||||||||||||||
| Price to EarningsP/E | -5.06 | -23.81 | -24.95 | -10.13 | -8.39 | -3.53 | -6.71 | -17.98 | -25.46 | -21.06 | -14.16 | |||||
| Price to BookP/B | 0.63 | 2.82 | 3.21 | 2.14 | 1.86 | 1.31 | 1.27 | 3.02 | 2.16 | 1.84 | 1.56 | |||||
| Enterprise Value | -49.61M | 321.21M | 354.96M | 141.83M | 96.09M | -62.64M | 42.27M | 242.00M | 350.93M | 232.21M | 154.68M | |||||
| EV to EBIT | 3.31 | -13.79 | -15.07 | -4.50 | -3.51 | 1.85 | -1.38 | -11.18 | -15.18 | -10.40 | -5.52 | |||||
| EV to EBITDA | 3.31 | -13.79 | -15.07 | -4.50 | -3.51 | 1.85 | -1.38 | -11.18 | -15.18 | -10.40 | -5.52 | |||||
| Market Capitalization | 71.86M | 516.31M | 529.96M | 298.85M | 217.61M | 115.18M | 175.17M | 364.76M | 532.70M | 425.26M | 366.38M | |||||
| Price to FCFP/FCF | -5.12 | -34.30 | -26.02 | -16.71 | -7.68 | -5.30 | -6.44 | -12.23 | -26.53 | -20.08 | -20.81 | |||||
| EV to FCF | 3.54 | -21.34 | -17.43 | -7.93 | -3.39 | 2.88 | -1.55 | -8.11 | -17.48 | -10.96 | -8.79 | |||||
| EV to CFO | 3.55 | -21.61 | -17.61 | -7.97 | -3.39 | 2.88 | -1.55 | -8.19 | -17.48 | -10.98 | -8.79 | |||||
| Return Ratios | ||||||||||||||||
| Return on Sales [ROS]ROS | -3,292.28% | |||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -85.61% | -46.82% | -44.68% | -59.80% | -76.89% | -110.23% | -103.46% | -79.56% | -57.67% | -39.86% | -40.14% | |||||
| Return on Assets [ROA]ROA | -68.26% | -39.33% | -38.11% | -47.34% | -61.30% | -80.19% | -75.67% | -65.62% | -48.46% | -33.72% | -34.54% |